How COVID-19 Is Delaying the FDA-Approval of This Highly Anticipated Wrinkle-Reducer

How COVID-19 Is Delaying the FDA-Approval of This Highly Anticipated Wrinkle-Reducer featured image
Photo Credits: Fancy/Veer/Corbis/ Getty Images | Image Used for Illustrative Purposes Only

The much buzzed about DAXI neurotoxin by Revance has hit a speed bump in getting it’s highly anticipated FDA-approval thanks to COVID-19. While many doctors and patients have been waiting patiently to get try this longer-lasting wrinkle relaxer—results from clinical trials suggest it can last up to 6 months, about 8 weeks longer than other neurotoxins—it seems like the wait is still on.

Approval of DAXI, which is short for DaxibotulinumtoxinA, has been delayed due to travel restrictions stemming from the pandemic. In a press release, Revance announced that FDA stated that the manufacturing facility located in Northern California has to be inspected as part of the approval process. Unfortunately, the agency’s travel restrictions associated with the COVID-19 pandemic has prevented that inspection from happening. 

For now, we wait. Many of the expert injectors we’ve spoken to say they are excited about having a toxin that is manufactured here in the U.S.  “It should translate to an easier experience buying, shipping and storing the product and it will not need refridgeration,” says Delray Beach, FL dermatologist Janet Allenby, MD. But as we are seeing, although DAXI has the homefield advantage, the COVID outbreak has created an obstacle that hopefully can be resolved quickly because this is one injectable everyone is excited to test out.

Related Posts

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.